First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma

B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, S. Négrier, J. McKendrick, A. Santoro, P. Pisa, B. Escudier

Research output: Contribution to journalArticle

Abstract

Background: In patients with untreated metastatic renal cell carcinoma (mRCC), progression-free survival (PFS) was longer with bevacizumab + interferon (IFN)-α than IFN + placebo (AVOREN trial). In this hypothesis-generating study, subgroup analysis was carried out to determine the effect of IFN dose reduction. Patients and methods: A total of 649 patients received IFN 9 MIU s.c. three times weekly plus bevacizumab 10 mg/kg or placebo every 2 weeks until disease progression. The IFN dose was reduced to 6 or 3 MIU with the development of IFN-attributed toxicity. Differences between treatment arms in PFS, response rate and tolerability were analysed in the reduced-dose group. Results: IFN dose was reduced in 131 patients in the bevacizumab + IFN arm and 97 patients in the IFN + placebo arm during the trial. PFS rates in the bevacizumab + reduced-dose IFN group were comparable with the total population (Kaplan-Meier estimates of event-free rate at 1 year: 0.524 versus 0.427). Bevacizumab + reduced-dose IFN was well tolerated, with substantial decreases in the rate of adverse events following dose reduction. Conclusion: This retrospective subgroup analysis suggests that the dose of IFN can be reduced to manage side-effects while maintaining efficacy in patients with mRCC receiving bevacizumab + IFN.

Original languageEnglish
Pages (from-to)1470-1476
Number of pages7
JournalAnnals of Oncology
Volume19
Issue number8
DOIs
Publication statusPublished - 2008

    Fingerprint

Keywords

  • Antiangiogenic therapy
  • Bevacizumab
  • Interferon-α
  • Renal cell carcinoma
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Melichar, B., Koralewski, P., Ravaud, A., Pluzanska, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Delva, R., Sevin, E., Négrier, S., McKendrick, J., Santoro, A., Pisa, P., & Escudier, B. (2008). First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology, 19(8), 1470-1476. https://doi.org/10.1093/annonc/mdn161